Matthew Gline received $163.3M in total compensation as Chief Executive Officer of Roivant Sciences Ltd. in FY2024. The largest component was $157.6M in stock awards. That’s up 22021% from FY2023. Source: SEC DEF 14A.
Executive Compensation Summary for Roivant Sciences Ltd.
Matthew Gline Salary and Compensation - Roivant Sciences Ltd. CEO Pay 2024
In fiscal year 2024, Matthew Gline, Chief Executive Officer of Roivant Sciences Ltd. (ROIV), received total compensation of $163.3 million.
Matthew Gline's compensation breakdown includes: base salary of $725K, bonus of $5.0 million, stock awards valued at $157.6 million, and other compensation of $12K.
Compared to fiscal year 2023, Matthew Gline's total compensation increased 22021% from $738K to $163.3 million.
Roivant Sciences Ltd. (ROIV) Executive Pay 2024
Roivant Sciences Ltd.'s top 6 named executive officers received combined total compensation of $438.2 million in fiscal year 2024.
The named executive officers disclosed in Roivant Sciences Ltd.'s 2024 proxy statement are:Matthew Gline (Chief Executive Officer) with total compensation of $163.3 million, Mayukh Sukhatme (M.D. President and Chief Investment Officer) with total compensation of $251.9 million, Eric Venker (M.D., Pharm.D. President and Chief Operating Officer) with total compensation of $11.8 million, Rakhi Kumar (Former Chief Accounting Officer) with total compensation of $4.7 million, Richard Pulik (Chief Financial Officer) with total compensation of $4.1 million, and Jennifer Humes (Chief Accounting Officer) with total compensation of $2.4 million.